Dolby Laboratories (NYSE:DLB) Earns Buy Rating from Rosenblatt Securities

Dolby Laboratories (NYSE:DLB)‘s stock had its “buy” rating reiterated by equities researchers at Rosenblatt Securities in a research note issued on Thursday,Benzinga reports. They currently have a $85.00 target price on the electronics maker’s stock. Rosenblatt Securities’ price target would indicate a potential upside of 62.91% from the company’s current price.

DLB has been the topic of several other reports. Barrington Research reiterated an “outperform” rating and issued a $90.00 target price on shares of Dolby Laboratories in a report on Monday, April 27th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Dolby Laboratories in a report on Friday, March 27th. Finally, Wall Street Zen upgraded shares of Dolby Laboratories from a “hold” rating to a “buy” rating in a report on Saturday, May 30th. Three analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $90.75.

Dolby Laboratories Trading Down 1.4%

DLB traded down $0.72 on Thursday, reaching $52.18. The stock had a trading volume of 165,458 shares, compared to its average volume of 762,419. Dolby Laboratories has a 12-month low of $51.78 and a 12-month high of $77.00. The business’s 50-day moving average price is $58.69 and its two-hundred day moving average price is $62.38. The company has a market cap of $4.94 billion, a P/E ratio of 20.64 and a beta of 0.81.

Dolby Laboratories (NYSE:DLB) last released its earnings results on Thursday, April 30th. The electronics maker reported $1.37 EPS for the quarter, topping analysts’ consensus estimates of $1.31 by $0.06. The business had revenue of $395.63 million during the quarter, compared to analysts’ expectations of $385.80 million. Dolby Laboratories had a net margin of 17.85% and a return on equity of 11.47%. The company’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.34 earnings per share. Dolby Laboratories has set its FY 2026 guidance at 4.300-4.450 EPS and its Q3 2026 guidance at 0.560-0.710 EPS. As a group, analysts predict that Dolby Laboratories will post 3.21 earnings per share for the current year.

Insider Buying and Selling at Dolby Laboratories

In other news, CMO Todd Pendleton sold 11,876 shares of the stock in a transaction dated Friday, May 22nd. The shares were sold at an average price of $54.55, for a total value of $647,835.80. Following the completion of the transaction, the chief marketing officer owned 41,480 shares in the company, valued at $2,262,734. This trade represents a 22.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Shriram Revankar sold 3,000 shares of the firm’s stock in a transaction dated Friday, May 15th. The shares were sold at an average price of $54.90, for a total transaction of $164,700.00. Following the transaction, the senior vice president owned 80,603 shares of the company’s stock, valued at $4,425,104.70. This trade represents a 3.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 39,791 shares of company stock worth $2,231,653 in the last quarter. 37.93% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dolby Laboratories

Several hedge funds have recently modified their holdings of DLB. Royal Bank of Canada boosted its position in shares of Dolby Laboratories by 3.5% in the first quarter. Royal Bank of Canada now owns 68,367 shares of the electronics maker’s stock worth $5,491,000 after acquiring an additional 2,298 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Dolby Laboratories by 218.8% in the first quarter. Goldman Sachs Group Inc. now owns 249,574 shares of the electronics maker’s stock worth $20,043,000 after acquiring an additional 171,288 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Dolby Laboratories by 5.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 238,216 shares of the electronics maker’s stock worth $19,131,000 after acquiring an additional 12,598 shares during the last quarter. Focus Partners Wealth acquired a new stake in shares of Dolby Laboratories in the first quarter worth approximately $390,000. Finally, EverSource Wealth Advisors LLC lifted its position in Dolby Laboratories by 273.3% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the electronics maker’s stock valued at $193,000 after buying an additional 1,902 shares in the last quarter. 58.56% of the stock is owned by institutional investors and hedge funds.

About Dolby Laboratories

Dolby Laboratories, Inc is a global leader in audio and imaging technologies, specializing in the development, licensing and deployment of solutions that enhance entertainment and communications experiences. The company’s core business revolves around creating advanced audio codecs, noise reduction systems and spatial sound technologies for a wide range of applications, including cinema, broadcast, gaming, streaming and personal devices. Dolby’s licensing model enables consumer electronics manufacturers, content creators and service providers to integrate its technologies into products such as televisions, smartphones, home theater systems and set-top boxes.

Among its flagship innovations are Dolby Atmos, an immersive audio format that delivers three-dimensional soundscapes for theaters and home systems; Dolby Digital and Dolby Digital Plus, widely adopted audio compression formats for broadcast and streaming; and Dolby Vision, a high-dynamic-range imaging technology that expands color, contrast and brightness in displays.